Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density (BMD) and disrupted bone architecture, predisposing the patient to increased fracture risk. Evidence from early genetic epidemiological studies has indicated a major role for genetics in the development of osteoporosis and the variation in BMD. In this study, we focused on two key genes in the endochondra...

Osteoporosis is a condition characterized by low bone mineral density (BMD) and micro-architectural changes in the bone tissue. The risk of osteoporosis is partly determined by genetic factors. The role of C677T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene has been investigated in postmenopausal osteoporosis. However, the relationship between MTHFR polymorphism and BMD is st...

Postmenopausal osteoporosis is a complicated and multi-factorial disease. To study the metabolic profiles and pathways activated in osteoporosis, Eight rats were oophorectomized (OVX group) to represent postmenopausal osteoporosis and the other eight rats were sham operated (Sham group) to be the control. The biochemical changes were assessed with metabolomics using a gas chromatography/time-of...

Postmenopausal osteoporosis is an asymptomatic skeletal disease that is often underdiagnosed and undertreated. Osteoporotic fractures are associated with substantial morbidity and mortality and impaired quality of life-socially, emotionally, and financially. Considering the growing burden of osteoporotic fractures worldwide, there remains an ongoing need for progress in the diagnosis of osteopo...

Osteoporosis constitutes a relevant health, social and economic problem of the contemporary world. As a chronic disease, often nicknamed the "silent thief", it is an object of the clinical research and a reason for many ambiguities. The most noticeable and basic symptom of osteoporosis is a low-energy fracture, which brings pain, physical disability, and a noticeable decrease in one's quality o...

The utility of procollagen type 1 N-terminal propeptide (P1NP) in the management of metabolic bone diseases remains a subject of debate since the reference ranges are not rigorously established and fail to account for many of the preanalytical variables. We aimed to establish reference intervals for P1NP level in healthy and osteoporotic postmenopausal females stratified by age, body mass index...

BACKGROUND To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and incident fractures. METHODS The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study measuring HRQoL...

Millions of women will be prescribed hormone replacement therapy (HRT) and be told that it will prevent osteoporosis occurring, despite the fact that there is doubt about its long term usefulness. Preventive measures outlined in this article are much more preferable, but need to be directed towards the whole population, not just menopausal women. The prevention of osteoporosis is an important p...

1. Apply an understanding of drug mechanisms to explain drug-induced osteoporosis and its consequences. 2. Use the diagnostic process to develop treatment and monitoring plans for drug-induced osteoporosis. 3. Assess for potential risk factors associated with druginduced osteoporosis. 4. Evaluate the epidemiologic literature to assess the absolute increase in risk of drug-induced osteoporosis a...